Pelthos Therapeutics (PTHS) Liabilities and Shareholders Equity (2022 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Liabilities and Shareholders Equity of $130.4 million for Q4 2025, up 9424.98% year-over-year from $1.4 million in Q4 2024, and up 3.14% quarter-over-quarter from $126.4 million in Q3 2025.
Pelthos Therapeutics (PTHS) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends
Pelthos Therapeutics' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $130.4 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity rose 9424.98% year-over-year to $130.4 million; the TTM figure through Dec 2025 stood at $258.6 million (up 2448.92% YoY), while the FY2025 annual figure was $130.4 million, up 9424.98% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $130.4 million, up from $126.4 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $130.4 million in Q4 2025, with the low at $55074.0 in Q4 2022.
- The 4-year median for Liabilities and Shareholders Equity is $1.8 million (2024), against an average of $26.9 million.
- Peak annual rise in Liabilities and Shareholders Equity reached 9424.98% in 2025, while the deepest fall reached 77.4% in 2025.
- Pelthos Therapeutics' Liabilities and Shareholders Equity stood at $55074.0 in 2022, then surged by 75.02% to $96391.0 in 2023, then surged by 1320.26% to $1.4 million in 2024, then surged by 9424.98% to $130.4 million in 2025.
- Business Quant data shows PTHS's Liabilities and Shareholders Equity at $130.4 million in Q4 2025, $126.4 million in Q3 2025, and $822850.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | 137.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.36 Mn |
| Dec 31, 2025 | 130.40 Mn |
| Sep 30, 2025 | 126.43 Mn |
| Jun 30, 2025 | 822,850.00 |
| Mar 31, 2025 | 911,179.00 |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 2.14 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Mar 31, 2024 | 4.03 Mn |
| Dec 31, 2023 | 96,391.00 |
| Dec 31, 2022 | 55,074.00 |